Translation
Original language
14.05.2026
How to Radically Extend the Human Lifespan
In this essay, I demonstrate how the individual stages of the SUL Method outlined in my upcoming publication “The SUL Method and Controlled Atom Technology for Radically Extending the Human Lifespan” [1] can be applied at the state level.
But first let us lay out the problem.
Demographic trends present a dual challenge: population aging in developed countries is putting an increasing strain on social systems, while the “young” population in developing countries is facing a shortage of decent jobs [2]. The answer may lie in the “active longevity” paradigm, where age ceases to be a limitation on productivity.
However, modern achievements in medicine, biotechnology, and human sciences are fragmented. Consolidating them within a single, logical, and phased global strategy could become the basis for long-term investment, the formation of new markets, and sustainable economic growth for entire regions.
The economic impact is clear: extending the healthy lifespan directly increases total capital, prolongs the duration of working life, reduces the cost of treating age-related diseases, and stimulates consumer demand. The technological base for this is already being created, but requires systematization and clear investment guidelines.
The proposed strategy is not a single technology, but a step-by-step system of measures where each subsequent level is based on the results of the previous level, creating a cumulative effect. The strategy is applicable in countries with different levels of development, starting with accessible measures and gradually incorporating advanced technologies.
Stage 1. “Foundation: Mass Health Culture.” Goal: the broadest possible implementation of proven non-drug practices. This includes government programmes to promote healthy eating, physical activity, stress management, and getting rid of poor habits. Example case: Singapore, where public health policies have ensured one of the highest healthy life expectancies in the world (74 years) [3].
Stage 2. “Personalization: Technologies for Monitoring Early Intervention.” Investments in networks of accessible preventive medicine centres equipped with genetic screening and biomarker analysis, and supported by AI-based platforms for interpreting data. The development of telemedicine will allow coverage of remote regions. The focus is shifting from the treatment of diseases to prediction and prevention.
Stage 3. “Biotech Optimization: Repair and Improvement.” The coordination of international research programmes in promising areas: gene therapy for hereditary diseases; cellular regeneration (stem cell technologies); and the development of safe and effective geroprotectors. The creation of open international databases of clinical trials will accelerate progress and minimize the duplication of effort [4].
Stage 4. “Convergence and Singularity: Targeted Health Design.” Strategic planning in nano- and picotechnologies for precision drug delivery and intracellular repair. The proclamation of the creation of the first artificial living cell by human design (“controlled atom technology”) as a long-term global goal (target year 2050). Not only will this solve the problem of organ rejection, but it will also become a point of singularity in biotechnology, giving rise to a new industry.
Specific proposals for implementation:
– Launch pilot projects in partner countries with different income levels to test different staged of the roadmap, tailored to local specifics.
– Create a Targeted Investment Fund to co-finance projects that correspond to the stages of the strategy, with the involvement of states, development institutions, and private capital.
– Establish an International Consortium under the auspices of Global Majority unions (BRICS, SCO). The objective of the Consortium would be to develop standards, coordinate research, and harmonize regulatory norms.
Implementing this strategy will make it possible:
In the economy – to create a new multi-billion-dollar market for technologies and services related to health and longevity. Increasing the duration of working life will directly impact GDP growth in participating countries [5].
In the social sphere – to radically increase the human development index and wellbeing of the population, reduce the burden on healthcare systems, and create millions of highly skilled jobs in new industries.
In geopolitics – to strengthen the technological sovereignty of, and cooperation among, the countries of the global majority, offering the world a positive and unifying goal, an alternative to the logic of confrontation.
Investing in the radical extension of human life is investing in the most important asset of the future: healthy, educated, and motivated people that would lead the global economy to new horizons.
1. Zakharov, A. (2026). The SUL Method and Controlled Atom Technology for Radically Extending the Human Lifespan.
2. United Nations. (2023). World Population Ageing 2023 Highlights.
3. Global Health Observatory of the World Health Organization. Healthy life expectancy (HALE) at birth.
4. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The Hallmarks of Aging. Cell, 153(6), 1194–1217.
5. The World Bank study “The Changing Wealth of Nations” and the methodology for calculating the Human Capital Index.
But first let us lay out the problem.
Demographic trends present a dual challenge: population aging in developed countries is putting an increasing strain on social systems, while the “young” population in developing countries is facing a shortage of decent jobs [2]. The answer may lie in the “active longevity” paradigm, where age ceases to be a limitation on productivity.
However, modern achievements in medicine, biotechnology, and human sciences are fragmented. Consolidating them within a single, logical, and phased global strategy could become the basis for long-term investment, the formation of new markets, and sustainable economic growth for entire regions.
The economic impact is clear: extending the healthy lifespan directly increases total capital, prolongs the duration of working life, reduces the cost of treating age-related diseases, and stimulates consumer demand. The technological base for this is already being created, but requires systematization and clear investment guidelines.
The proposed strategy is not a single technology, but a step-by-step system of measures where each subsequent level is based on the results of the previous level, creating a cumulative effect. The strategy is applicable in countries with different levels of development, starting with accessible measures and gradually incorporating advanced technologies.
Stage 1. “Foundation: Mass Health Culture.” Goal: the broadest possible implementation of proven non-drug practices. This includes government programmes to promote healthy eating, physical activity, stress management, and getting rid of poor habits. Example case: Singapore, where public health policies have ensured one of the highest healthy life expectancies in the world (74 years) [3].
Stage 2. “Personalization: Technologies for Monitoring Early Intervention.” Investments in networks of accessible preventive medicine centres equipped with genetic screening and biomarker analysis, and supported by AI-based platforms for interpreting data. The development of telemedicine will allow coverage of remote regions. The focus is shifting from the treatment of diseases to prediction and prevention.
Stage 3. “Biotech Optimization: Repair and Improvement.” The coordination of international research programmes in promising areas: gene therapy for hereditary diseases; cellular regeneration (stem cell technologies); and the development of safe and effective geroprotectors. The creation of open international databases of clinical trials will accelerate progress and minimize the duplication of effort [4].
Stage 4. “Convergence and Singularity: Targeted Health Design.” Strategic planning in nano- and picotechnologies for precision drug delivery and intracellular repair. The proclamation of the creation of the first artificial living cell by human design (“controlled atom technology”) as a long-term global goal (target year 2050). Not only will this solve the problem of organ rejection, but it will also become a point of singularity in biotechnology, giving rise to a new industry.
Specific proposals for implementation:
– Launch pilot projects in partner countries with different income levels to test different staged of the roadmap, tailored to local specifics.
– Create a Targeted Investment Fund to co-finance projects that correspond to the stages of the strategy, with the involvement of states, development institutions, and private capital.
– Establish an International Consortium under the auspices of Global Majority unions (BRICS, SCO). The objective of the Consortium would be to develop standards, coordinate research, and harmonize regulatory norms.
Implementing this strategy will make it possible:
In the economy – to create a new multi-billion-dollar market for technologies and services related to health and longevity. Increasing the duration of working life will directly impact GDP growth in participating countries [5].
In the social sphere – to radically increase the human development index and wellbeing of the population, reduce the burden on healthcare systems, and create millions of highly skilled jobs in new industries.
In geopolitics – to strengthen the technological sovereignty of, and cooperation among, the countries of the global majority, offering the world a positive and unifying goal, an alternative to the logic of confrontation.
Investing in the radical extension of human life is investing in the most important asset of the future: healthy, educated, and motivated people that would lead the global economy to new horizons.
1. Zakharov, A. (2026). The SUL Method and Controlled Atom Technology for Radically Extending the Human Lifespan.
2. United Nations. (2023). World Population Ageing 2023 Highlights.
3. Global Health Observatory of the World Health Organization. Healthy life expectancy (HALE) at birth.
4. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The Hallmarks of Aging. Cell, 153(6), 1194–1217.
5. The World Bank study “The Changing Wealth of Nations” and the methodology for calculating the Human Capital Index.
Read full text
